{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-23-009746","form_type":"8-K","ticker":"TLPH","cik":"0001427925","company_name":"TALPHERA, INC.","filed_at":"2023-04-07T23:59:59+00:00","discovered_at":"2026-05-14T18:03:38.827514+00:00","generated_at":"2026-06-17T04:29:53.390432+00:00","sec_items":["1.02","2.01","7.01","9.01"],"event_type":"m_and_a","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"AcelRx closes sale of DSUVIA to Alora for up to $116.5M in milestones; repays Oxford loan","bullets":["Closed divestment of DSUVIA to Alora Pharmaceuticals on April 3, 2023; received ~$2.7M from Aguettant and Alora at closing.","Consideration includes $1.1M upfront, 15% royalty on commercial sales, 75% on DoD sales, and up to $116.5M in milestones.","Fully repaid $5.4M Oxford loan with no prepayment penalties; company becomes debt-free after transaction.","Pro forma financials reflect removal of DSUVIA-related revenues and expenses; focus shifts to Niyad and Fedsyra pipeline.","Amended Aguettant agreements include €1.5M complementary payment and termination of certain sales milestones."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-23-009746","json":"https://secwatch.observer/filing/0001437749-23-009746.json","markdown":"https://secwatch.observer/filing/0001437749-23-009746.md","text":"https://secwatch.observer/filing/0001437749-23-009746.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1427925/000143774923009746/0001437749-23-009746-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1427925/000143774923009746/acrx20230406_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-17T04:29:53.390432+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"b1c1f0399c68d082fd2b84547b65c96e48836ee0","claim":"TALPHERA, INC. completed a disposition involving Vertical Pharmaceuticals, LLC (a wholly owned subsidiary of Alora Pharmaceuticals, LLC) for approximately $2.7 million from Alora Pharmaceuticals and Aguettant (closed 2023-04-03).","evidence_excerpt":"ex_498276.htm Exhibit 99.1 AcelRx Pharmaceuticals Announces Closing of Divestment of DSUVIA ® to Alora Pharmaceuticals In connection with closing, AcelRx received approximately $2.7 million from Alora Pharmaceuticals and Aguettant AcelRx announces full repayment of its senior loan with Oxford Finance HAYWARD, Calif., April 5, 2023 -- AcelRx Pharmaceuticals, Inc.","evidence_source":"SEC 8-K Item 2.01/5.01","evidence_url":"https://www.sec.gov/Archives/edgar/data/1427925/000143774923009746/0001437749-23-009746-index.htm","confidence":0.9,"family_label":"M&A Transactions","details":[{"label":"Action","value":"disposition"},{"label":"Counterparty","value":"Vertical Pharmaceuticals, LLC (a wholly owned subsidiary of Alora Pharmaceuticals, LLC)"},{"label":"Consideration","value":"approximately $2.7 million from Alora Pharmaceuticals and Aguettant"},{"label":"Closing","value":"2023-04-03"}],"fact_type":"ma_transaction"},{"claim_id":"f657fdee66821c6e7c407f59d7a188cff47b6b1f","claim":"TALPHERA, INC. terminated Loan and Security Agreement with Oxford Finance LLC valued at $5.4 million outstanding at December 31, 2022 (effective 2023-04-07).","evidence_excerpt":"On May 30, 2019, the Companyentered into a Loan and Security Agreement, or the Loan Agreement, with Oxford Finance LLC, or Oxford. Under the Loan Agreement, Oxford made a term loan to the Company in an aggregate principal amount of $25.0 million, or the Loan, which was funded on May 30, 2019.","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1427925/000143774923009746/0001437749-23-009746-index.htm","confidence":0.85,"family_label":"Material Agreements","details":[{"label":"Action","value":"termination"},{"label":"Agreement","value":"credit facility"},{"label":"Counterparty","value":"Oxford Finance LLC"},{"label":"Value","value":"$5.4 million outstanding at December 31, 2022"},{"label":"Effective","value":"2023-04-07"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}